The involvement of miR-181a/b as a significant factor in the drug resistance of melanoma was analyzed by Barbato et al. [61] by identifying changes of expression in melanoma cell lines sensitive and resistant to the BRAF inhibitor dabrafenib. The gene discussed is BRAF; the disease is melanoma.